GlycoMimetics stockholders approve proposed Crescent Biopharma merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2025
0mins
Should l Buy ?
Merger Approval: GlycoMimetics' stockholders have approved the merger with Crescent Biopharma and related proposals, including a reverse stock split of 1-for-100.
Trading Changes: The combined company's stock is set to begin trading under the new name "Crescent Biopharma, Inc." on June 16, 2025, on The Nasdaq Capital Market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
